Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVANCE THERAPEUTICS, INC.

(RVNC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Revance Therapeutics, Inc. Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

10/12/2021 | 07:10pm EDT

Revance Therapeutics, Inc. responds to the public disclosure of its Form 483 pursuant to a Freedom of Information Act (FOIA) request that was directed to the FDA. The Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under FDA review and the company continues to anticipate FDA approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines in 2021. Revance notes that the issuance of a Form 483 following the conclusion of an on-site inspection is not uncommon. A Form 483 lists observations made by FDA representatives during the inspection of a facility. A Form 483 does not constitute a final agency determination. Revance provided its response to the Form 483 in July 2021 following a pre-approval inspection and is currently awaiting the FDA’s decision on its BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines. The company remains confident in the quality of its BLA submission and continues to anticipate FDA approval in 2021.


© S&P Capital IQ 2021
All news about REVANCE THERAPEUTICS, INC.
10/18REVANCE THERAPEUTICS : Lost Money in Revance Therapeutics, Inc.?
BU
10/18RVNC EQUITY ALERT : ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc...
PR
10/18Health Care Stocks Sputtering in Late Trade
MT
10/18ADEMI LLP : Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.
PR
10/18Top Midday Decliners
MT
10/18Health Care Stocks Weighing on Broader Monday Markets
MT
10/18REVANCE THERAPEUTICS : Piper Sandler Adjusts Price Target for Revance Therapeutics to $30 ..
MT
10/18REVANCE THERAPEUTICS : HC Wainwright Adjusts Revance Therapeutics' Price Target to $18 fro..
MT
10/18REVANCE THERAPEUTICS : Needham & Co Adjusts Revance Therapeutics PT to $25 From $45, Maint..
MT
10/18INVESTIGATION NOTICE : The Schall Law Firm Announces it is Investigating Claims Against Re..
PR
More news
Analyst Recommendations on REVANCE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 78,8 M - -
Net income 2021 -301 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,52x
Yield 2021 -
Capitalization 1 133 M 1 133 M -
Capi. / Sales 2021 14,4x
Capi. / Sales 2022 7,72x
Nbr of Employees 470
Free-Float 96,8%
Chart REVANCE THERAPEUTICS, INC.
Duration : Period :
Revance Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVANCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 15,78 $
Average target price 33,20 $
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Mark J. Foley President, Chief Executive Officer & Director
Tobin C. Schilke Chief Financial Officer
Angus C. Russell Chairman
Abhay Joshi COO & President-Research & Development
Roman G. Rubio Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
REVANCE THERAPEUTICS, INC.-44.32%1 133
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121